Avanir Pharmaceuticals (AVNR) Misses Q2 Loss Views by 1c/Share
Tweet Send to a FriendGet Alerts AVNR Hot Sheet
Price: $4.43 -4.11%
EPS Growth %: +25.0%
Financial Fact:
Loss from operations: -15.48M
Today's EPS Names:
CEDU, CHC, CIDM, More
EPS Growth %: +25.0%
Financial Fact:
Loss from operations: -15.48M
Today's EPS Names:
CEDU, CHC, CIDM, More
Trade AVNR Now!
Avanir Pharmaceuticals (NASDAQ: AVNR) reported Q2 EPS of ($0.13), $0.01 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $10 million versus the consensus estimate of $7.81 million.
For earnings history and earnings-related data on Avanir Pharmaceuticals (AVNR) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
For earnings history and earnings-related data on Avanir Pharmaceuticals (AVNR) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Jabil Circuit (JBL) Tops Q3 EPS by 2c; Issues Light Q4 Outlook; Will Realign Global Ops
- Crown Crafts, Inc. (CRWS) Posts Flat Q4 EPS of 19c
- PVH Corp. (PVH) Tops Q1 EPS by 56c; Issues Q2 EPS, Revs Outlook
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
